Orally bioavailable glutamine antagonist prodrug JHU-083 penetrates mouse brain and suppresses the growth of MYC-driven medulloblastoma

Authors

Allison R. Hanaford, Johns Hopkins University
Jesse Alt, Johns Hopkins University
Rana Rais, Johns Hopkins University
Sabrina Z. Wang, Johns Hopkins University
Harpreet Kaur, Johns Hopkins University
Daniel L.J. Thorek, Washington University School of Medicine in St. Louis
Charles G. Eberhart, Johns Hopkins University
Barbara S. Slusher, Johns Hopkins University
Allison M. Martin, Johns Hopkins University
Eric H. Raabe, Johns Hopkins University

Journal

Translational Oncology

Publication Date

2019

Volume

12

Issue

10

First Page

1314

Last Page

1322

Document Type

Open Access Publication

DOI

10.1016/j.tranon.2019.05.013

Rights and Permissions

Hanaford AR, Alt J, Rais R, Wang SZ, Kaur H, Thorek DLJ, Eberhart CG, Slusher BS, Martin AM, Raabe EH (2019) Orally bioavailable glutamine antagonist prodrug JHU-083 penetrates mouse brain and suppresses the growth of MYC-driven medulloblastoma. Translational Oncology, 12(10):1314-1322. https://doi.org/10.1016/j.tranon.2019.05.013 Under a Creative Commons license

Recommended Citation

Hanaford, Allison R.; Alt, Jesse; Rais, Rana; Wang, Sabrina Z.; Kaur, Harpreet; Thorek, Daniel L.J.; Eberhart, Charles G.; Slusher, Barbara S.; Martin, Allison M.; and Raabe, Eric H., "Orally bioavailable glutamine antagonist prodrug JHU-083 penetrates mouse brain and suppresses the growth of MYC-driven medulloblastoma." Translational Oncology. 12, 10. 1314 - 1322. (2019).
https://digitalcommons.wustl.edu/open_access_pubs/8035